Cell and Gene Therapy Advances Outpace Healthcare System Readiness
核心洞察
Cell and gene therapies can correct or replace faulty genetic instructions, with some treatments such as CAR T cell therapy (搜索) reprogramming a patient's own cells to eliminate disease.
A single treatment can produce a durable or potentially curative response, reducing years of ongoing therapy and its associated burden, side effects, and cost.
Only an estimated 20% of eligible patients actually receive cell and gene therapies, with reimbursement delays exceeding 100 days versus a typical 45-day turnaround.
Cell and gene therapies are introducing a fundamentally different possibility in medicine: changing the biology itself. Some gene therapies can correct or replace faulty genetic instructions, while others, such as CAR T cell therapy (搜索), reprogram a patient's own cells to find and eliminate disease. For some patients, a single treatment can produce a durable or potentially curative response, reducing the need for years of ongoing therapy and the associated burden, side effects, and cost.
Sakshi Walia, senior executive-cell and gene therapy at Intas Pharmaceuticals, described the field as "revolutionizing modern medicine by offering treatments that address diseases at their root cause rather than simply managing symptoms." These advanced therapies use living cells or genetic modifications to repair, replace, or restore normal biological function, opening new possibilities for patients with rare genetic disorders, cancers, and other life-threatening diseases.
A Shift From Managing Symptoms to Correcting Biology
Modern medicine has become increasingly precise, with targeted therapies that act on specific drivers of disease. However, many of these therapies require patients to remain on treatment to maintain control. Cell and gene therapies introduce a different paradigm, as Walia explained: "By targeting faulty genes responsible for inherited conditions, gene therapy aims to provide long-lasting or even curative outcomes."
Cell therapy, by contrast, uses living cells—such as stem cells or immune cells—to regenerate damaged tissues or enhance the body's ability to fight disease. A notable example is CAR-T cell therapy, where a patient's immune cells are genetically engineered to recognize and destroy cancer cells. These therapies are creating new possibilities for patients with conditions like spinal muscular atrophy (搜索) or hemophilia, including diseases for which treatment options were historically limited.
The Precision Medicine Frontier
"The power of cell and gene therapy lies in its precision," Walia stated. Advances in technologies such as CRISPR (搜索) gene editing have enabled scientists to make highly targeted changes to DNA, creating personalized treatments tailored to individual patients. This shift from "one-size-fits-all" medicine to precision medicine is transforming healthcare and providing hope for conditions that previously had limited treatment options.
The scale of the field is expanding rapidly. The American Society of Gene + Cell Therapy estimates there are currently more than 4,000 cell and gene therapies in development. Some reports estimate the U.S. will spend more than $25 billion on gene therapies alone in 2026.
The Economics of Curative Therapy
Cell and gene therapy has the potential to treat previously untreatable genetic disorders and cancers, such as advanced leukemia (搜索) and sickle cell disease (搜索). These therapies also offer cost savings to both patients and health systems. Instead of a patient returning repeatedly for care as symptoms emerge, cell and gene therapies may eradicate the problem once and for all.
For example, the cost of a gene therapy to treat hemophilia B (搜索) can climb to $3.5 million for a single treatment. However, the 10-year cost of ongoing treatment for the same condition can add up to much more—and that does not account for the patient's extreme daily burdens, including chronic pain, physical mobility limitations, and psychological distress.
While immeasurably valuable, the steep upfront costs associated with cell and gene therapy can severely limit access. This challenges healthcare organizations to rethink the economics and infrastructure of chronic care, requiring payers, health systems, and pharmaceutical companies to work together to manage costs and improve access.
Barriers to Patient Access
The barriers to expanding access can be divided into three interconnected areas: cost, finding the right patients, and improving clinical expertise.
Payers are skeptical of including cell and gene therapy in healthcare contracts because they want to see more predictability in patient outcomes. Predictability is difficult to prove when only an estimated 20% of patients eligible for cell and gene therapies actually receive them. As a result, many cell and gene therapies are handled on a single case agreement between the payer and provider, which can lead to reimbursement delays of well over 100 days—compared to the typical 45-day reimbursement turnaround for more common treatments.
The majority of patients eligible for cell and gene therapy never end up receiving this care. Most healthcare facilities offering these treatments are top-tier health systems and academic centers, typically found in urban areas. For patients in rural areas, access requires more coordination, support, and financial means to travel to larger medical centers, along with improved communication between rural and urban providers.
Understanding and awareness is also limited by treatment complexity, specialized infrastructure gaps, and small patient populations. These cutting-edge modalities require rigorous handling protocols, long-term tracking, and medical training—details that community healthcare settings are not yet equipped to provide.
A Collaborative Path Forward
These barriers are deeply interconnected. Cost and predictability cannot improve without broader patient access, and expanding access requires stronger communication between community providers and health systems, along with greater clinical expertise to identify and refer eligible patients.
Addressing these barriers will take a collaborative approach with better coordination among providers, payers, and health systems, combined with stronger data-sharing, patient identification, and clinical education. Despite challenges such as high costs, complex manufacturing processes, and regulatory considerations, cell and gene therapy continues to advance rapidly. As technologies improve and become more accessible, these therapies are expected to redefine the treatment of genetic diseases and many other conditions.